Dr. Reddy’s Laboratories has received Semaglutide Injection Canada approval from Health Canada. Moreover, this Semaglutide Injection Canada approval positions the company as the first to secure authorization for the generic version in Canada. Additionally, the company obtained the Notice of Compliance ahead of the review target date. Therefore, this marks a major regulatory achievement for Dr. Reddy’s Laboratories.
The Semaglutide Injection Canada approval covers 2 mg per pen (1.34 mg/mL) and 4 mg per pen (1.34 mg/mL). Furthermore, Dr. Reddy’s has already started launch preparations for the Canadian market. Consequently, the company aims to expand patient access to affordable diabetes treatment options.
Growing Diabetes Burden in Canada
According to the Public Health Agency of Canada, around 3.9 million people live with diagnosed diabetes. In addition, nearly 6% of adults have prediabetes across the country. Therefore, the risk of developing type 2 diabetes continues to rise. Moreover, population aging further increases this healthcare challenge. GLP-1 receptor agonists, including semaglutide, show strong clinical evidence. They improve glycemic control measured through HbA1c levels in type 2 diabetes patients. Furthermore, Canada represents the second-largest global market for semaglutide therapies. Thus, demand for advanced diabetes care continues to grow steadily.
Strengthening Complex Generics Capability
Dr. Reddy’s highlighted its expertise in peptide-based therapeutics. Additionally, the company supports in-house API development and formulation capabilities. The API is fully produced internally, ensuring quality control and consistency. Meanwhile, OneSource Specialty Pharma Limited handles finished product manufacturing. This Semaglutide Injection Canada approval reinforces Dr. Reddy’s global regulatory strength. Moreover, it strengthens the company’s position in complex generic development.
Erez Israeli, Chief Executive Officer, Dr. Reddy’s, said:
“The approval of our generic Semaglutide Injection by Health Canada represents a significant milestone in our GLP-1 journey and underscores our expertise in complex product development, peptide science, and our ability to meet stringent global regulatory standards. Canada remains a priority market for us. As the first company to receive market authorization for generic Semaglutide Injection in Canada, we remain dedicated to expanding access to innovative, high‑quality, affordable GLP‑1 treatments for patients with diabetes in the country. Additionally, with our in-house development capabilities, we are committed to ensuring a reliable and consistent supply of this important therapy for Canadian patients. This approval further fortifies our long-standing presence in Canada and enhances our diabetes management portfolio for regulated markets.”
Therapeutic Use Overview
Semaglutide Injection is used once weekly for adults with type 2 diabetes. It supports glycemic control along with diet and exercise. Additionally, it is prescribed when metformin is unsuitable or insufficient. However, it is not indicated for type 1 diabetes or diabetic ketoacidosis. Moreover, it should not replace insulin therapy in clinical use. Healthcare providers should refer to the full product monograph. It includes safety details, warnings, and adverse reactions.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
